Drug used in breast and ovarian cancer could lead to safer, more effective treatment for neuroblastoma 25 Jun 2020 A type of drug known as a PARP inhibitor, already used to treat breast and ovarian cancer, may be useful in treating children with high-risk neuroblastoma – a common childhood tumour with a low survival rate. Find out more Show/Hide
Prostate cancer gets first gene-targeted medicines 21 May 2020 The Institute of Cancer Research, London, has strongly welcomed the approval by the US Food and Drug Administration (FDA) of the genetically targeted drug olaparib for some men with advanced prostate cancer. Find out more Show/Hide
Major trial shows breast cancer drug can hit prostate cancer Achilles heel 28 Apr 2020 A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports. Find out more Show/Hide
ICR research showcased in major new Science Museum gallery documenting history of medicine 29 Jan 2020
ESMO 2019: Breast and ovarian cancer drug outperforms targeted hormone therapy in some men with advanced prostate cancer 30 Sep 2019
ICR calls for wider gene testing in ovarian cancer after approval of olaparib earlier in treatment for women with BRCA mutations 26 Jul 2019
ASCO 2019: Breast cancer drug effective in 80 per cent of men with BRCA-mutant prostate cancer 05 Jun 2019